A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma

Sponsor
Sinocelltech Ltd.
Study ID
NCT07562022
Phase
PHASE3
Status
Recruiting
Apply to this trial

Conditions

  • Follicular Lymphoma (FL)

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • SCTB35 injection — DRUG
    SCTB35 will be subcutaneously administered at a dose as specified
  • Rituximab — DRUG
    Intravenous Infusion
  • Lenalidomide — DRUG
    Oral Capsules

Study Details

The purpose of this study is to evaluate the efficacy and safety of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular lymphoma (FL).

Key Dates

First listed
May 1, 2026
Start date
Jun 9, 2026
Status verified
Aug 2026
Primary completion
May 31, 2028
Completion
Jun 30, 2029

Study Design

Enrollment
93 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: SCTB35 and Lenalidomide
  • Active Comparator: Rituximab and Lenalidomide

Primary Outcome Measure

Adverse Events [ Time Frame: Up to approximately 3 years ]

Related Studies